Appeal No. 1996-2216
Application No. 08/087,058
line 46 - col. 3, line 32). Again, the examiner has failed to establish a pathophysiological
nexus between these diseases and inflammatory skin disorders, intestinal disorders or
purpura which would provide a motivation to treat a different disease with the therapeutics
of EP '611 and/or Lezdey with a reasonable expectation of success. While the examiner
states that "[o]ne of the symptoms of SLE (i.e., systemic lupus erythrematosus) is a
necrotizing, inflammatory skin disorder" (answer, page 4), the examiner did not point out,
and we do not find were, EP '611 discloses a necrotizing, inflammatory skin disorder to be
a specific symptom of SLE.
The remaining references, Pelzer, Glover and Sims, do not overcome the
deficiencies of the Kitano, Naka, EP '611 or Lezdey. Pelzer describes a process for
purifying C1 inactivator, which C1 inactivator inactivates C1 esterase in the complement
system, "controls" blood clotting enzymes, and is the medicant of choice for hereditary
angioedema (col. 1, lines 7-23). Sims prevents platelet and endothelial cell activation and
cytolysis by complement proteins by administration of an 18 kDa C5b-9 inhibitory protein
that is expressed on erythrocyte membranes (abstract). Glover discloses serine protease
inhibitor peptides adapted to provide enhanced selectivity and/or potency for a target
protease, including proteases involved in blood clotting and clot degradation and in
complement activation (col. 4, lines 53-67).
5
Page: Previous 1 2 3 4 5 6 7 8 Next
Last modified: November 3, 2007